Commure vs DeepScribe
Both sell documentation with coding attached; the resemblance stops there. Commure, the General Catalyst backed roll up of Athelas, Augmedix, and Memora, treats the note as the front end of claims automation and sells oversight as a spectrum: Go for AI drafted notes, Assist adding specialist review, and Live with synchronous human documentation, across a claimed 50 plus EHRs and a reported 250,000 plus providers. DeepScribe treats the note as a specialty craft: oncology as its center of gravity with a reported 40 percent of US cancer care visits, tuned models for six further specialties, HCC, CPT, and ICD-10 suggestions built into the note, and the highest independent rating in the lane at 98.8 on the KLAS Emerging Company Spotlight. If your failure mode is clinicians or specialties that still need a human in the documentation loop, or notes that must feed claims automation, start with Commure. If your failure mode is complex specialty documentation that generalist scribes get wrong, start with DeepScribe. Neither publishes pricing.
- Oversight is a dial: Go delivers AI drafted notes, Assist adds specialist review, and Live provides synchronous human documentation, the only purchasable human review in this pairing.
- Estate and procurement reach: more than 50 EHRs including Epic, Oracle Health, and MEDITECH across ambulatory and acute settings, a reported 250,000 plus providers, and a January 2025 Vizient contract giving member health systems a negotiated path.
- Documentation feeds revenue cycle: ambient output flows into autonomous coding, clinical documentation integrity, and claims automation, backed by a public trust center, a published standard Business Associate Agreement, and stated data export in FHIR, CSV, and JSON.
- Specialty depth is the requirement: oncology first with a reported 5 million oncology visits a year and roughly 40 percent of US cancer care visits documented, plus tuned models for cardiology, urology, gastroenterology, orthopedics, neurology, and nephrology.
- The independent signal is one sided: a 98.8 KLAS Emerging Company Spotlight score with A plus marks across all six categories, 2025 KLAS Top 5 rankings, and an August 2025 Journal of Clinical Pathways study in oncology, where Commure's clinical evidence is unassessed on this index.
- Coding lives in the note: bidirectional integration reads the chart before the visit and writes structured data into discrete EHR fields after, with HCC, CPT, and ICD-10 suggestions built into the note, in more than 110 languages.
Side-by-Side
| Axis | C Commure |
D DeepScribe |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | — | |
| Model and Technology Transparency | — | — |
| Clinical and Operational Evidence | — | |
| AI Safety and PHI Stewardship | — | |
| HIPAA and BAA Posture | — | |
| Security Certifications and Trust Center | — | |
| FDA and Regulatory Status | — | — |
| AI Governance and Bias Disclosure | — | — |
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | — | |
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Provider and visit figures for both vendors are vendor published, including Commure's 250,000 plus providers and DeepScribe's oncology share. DeepScribe's KLAS scores are buyer survey based, and the Emerging Company Spotlight is a different KLAS instrument from the Best in KLAS category awards held elsewhere in this lane; Commure's clinical evidence is unassessed on this index. Two Commure trust center caveats are recorded: the independent audit claim is ambiguously worded with no named certification or date, with the SOC 2 Type 2 reference attaching to its data centers rather than to Commure itself, and the purpose limitation language does not state whether PHI is used to train models. Neither vendor publishes pricing. Third party estimates place DeepScribe at $350 to $500 per provider per month with some reports near $750; no third party figure is recorded for Commure. All estimates are unconfirmed.